Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Merck
Boehringer Ingelheim
Moodys
McKesson

Last Updated: June 3, 2023

Patent: 8,568,766


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 8,568,766
Title:Peptides and peptide mimetics to treat pathologies associated with eye disease
Abstract: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection.
Inventor(s): Anantharamaiah; Gattadahalli M. (Birmingham, AL), Fogelman; Alan M. (Beverly Hills, CA), Navab; Mohamad (Los Angeles, CA), Rudolf; Martin (Lubeck, DE)
Assignee:
Application Number:12/027,728
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,568,766
Patent Claims:see list of patent claims

Details for Patent 8,568,766

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2020-08-24
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 06/30/2006 ⤷  Try a Trial 2020-08-24
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 08/10/2012 ⤷  Try a Trial 2020-08-24
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 10/13/2016 ⤷  Try a Trial 2020-08-24
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 03/20/2018 ⤷  Try a Trial 2020-08-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Medtronic
Mallinckrodt
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.